TANGO THERAPEUTICS INC (TNGX) — insider trading
Health Care · NASDAQ
TANGO THERAPEUTICS INC (TNGX) has 46 reported SEC Form 4 insider transactions in our data, including 16 open-market sales among the most recent 46 (latest 2026-10-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 27,000 | — | $0 | Form 4 |
| 2026-10-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 600 | $25.32 | $15.2K | Form 4 |
| 2026-10-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 26,400 | $24.45 | $645.6K | Form 4 |
| 2026-10-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 27,000 | $5.20 | $140.4K | Form 4 |
| 2026-09-22 | Newcomb Jessica | Officer (Principal Accounting Officer) | Open-market sale | 2,400 | $25.17 | $60.4K | Form 4 |
| 2026-09-22 | Newcomb Jessica | Officer (Principal Accounting Officer) | Open-market sale | 5,100 | $23.97 | $122.2K | Form 4 |
| 2026-09-22 | Newcomb Jessica | Officer (Principal Accounting Officer) | Open-market sale | 700 | $22.80 | $16.0K | Form 4 |
| 2026-09-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 27,000 | — | $0 | Form 4 |
| 2026-09-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 27,000 | $22.37 | $603.9K | Form 4 |
| 2026-09-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 27,000 | $5.20 | $140.4K | Form 4 |
| 2026-08-03 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 27,000 | — | $0 | Form 4 |
| 2026-08-03 | Crystal Adam | Officer (President, R&D) | Open-market sale | 21,733 | $27.35 | $594.4K | Form 4 |
| 2026-08-03 | Crystal Adam | Officer (President, R&D) | Open-market sale | 5,267 | $26.79 | $141.1K | Form 4 |
| 2026-08-03 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 27,000 | $5.20 | $140.4K | Form 4 |
| 2026-07-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 27,000 | — | $0 | Form 4 |
| 2026-07-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 7,371 | $30.25 | $222.9K | Form 4 |
| 2026-07-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 19,629 | $29.34 | $576.0K | Form 4 |
| 2026-07-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 27,000 | $5.20 | $140.4K | Form 4 |
| 2026-06-19 | Azelby Robert | Director | Grant / award / vesting (derivative) | 35,910 | — | $0 | Form 4 |
| 2026-06-19 | Azelby Robert | Director | Grant / award / vesting | 5,740 | — | $0 | Form 4 |
| 2026-06-05 | Lee Sung | Director | Grant / award / vesting (derivative) | 3,570 | — | $0 | Form 4 |
| 2026-06-05 | Lee Sung | Director | Grant / award / vesting | 570 | — | $0 | Form 4 |
| 2026-06-05 | Rothenberg Mace | Director | Grant / award / vesting (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-06-05 | Rothenberg Mace | Director | Grant / award / vesting | 4,000 | — | $0 | Form 4 |
| 2026-06-05 | Calhoun Lesley Ann | Director | Grant / award / vesting (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-06-05 | Calhoun Lesley Ann | Director | Grant / award / vesting | 4,000 | — | $0 | Form 4 |
| 2026-06-05 | Ketchum John B | Director | Grant / award / vesting (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-06-05 | Ketchum John B | Director | Grant / award / vesting | 4,000 | — | $0 | Form 4 |
| 2026-06-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 27,000 | — | $0 | Form 4 |
| 2026-06-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 20,860 | $23.06 | $480.9K | Form 4 |
| 2026-06-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 6,140 | $22.25 | $136.6K | Form 4 |
| 2026-06-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 27,000 | $5.20 | $140.4K | Form 4 |
| 2026-05-01 | Gall Matthew | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 240,000 | — | $0 | Form 4 |
| 2026-05-01 | Gall Matthew | Officer (Chief Financial Officer) | Grant / award / vesting | 40,000 | — | $0 | Form 4 |
| 2026-05-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 27,000 | — | $0 | Form 4 |
| 2026-05-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 1,100 | $22.00 | $24.2K | Form 4 |
| 2026-05-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 25,900 | $21.19 | $548.9K | Form 4 |
| 2026-05-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 27,000 | $5.20 | $140.4K | Form 4 |
| 2026-04-29 | Lee Sung | Director | Grant / award / vesting (derivative) | 5,200 | — | $0 | Form 4 |
| 2026-04-29 | Lee Sung | Director | Grant / award / vesting | 12,300 | — | $0 | Form 4 |
| 2026-04-15 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 38,460 | — | $0 | Form 4 |
| 2026-04-15 | Crystal Adam | Officer (President, R&D) | Open-market sale | 38,460 | $25.00 | $961.5K | Form 4 |
| 2026-04-15 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 38,460 | $5.20 | $200.0K | Form 4 |
| 2026-04-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion (derivative) | 27,000 | — | $0 | Form 4 |
| 2026-04-01 | Crystal Adam | Officer (President, R&D) | Open-market sale | 27,000 | $21.20 | $572.5K | Form 4 |
| 2026-04-01 | Crystal Adam | Officer (President, R&D) | Option exercise / conversion | 27,000 | $5.20 | $140.4K | Form 4 |
Ask the chat about TNGX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: TANGO THERAPEUTICS INC (TNGX).
Last updated 2026-10-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.